Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Tools, Biomarkers Needed to Identify Immune-Related Toxicities

September 6, 2017
By Vamsidhar Velcheti, MD
Video

This video reviews the need for biomarkers and tools that could identify those at high risk of immune-related toxicities among patients undergoing immunotherapy treatment.

In this video, Vamsidhar Velcheti, MD, of the Cleveland Clinic in Cleveland, Ohio, discusses the need for tools and biomarkers to identify those at high risk of immune-related toxicities among patients undergoing immunotherapy treatment, and reviews some of the dangerous toxicities that can occur.

Velcheti gave a presentation on this topic earlier this year during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content

Phase 2b findings demonstrate improved 2-year survival outcomes with OST-HER2 compared with historical control data.

OST-HER2 Yields Significant Survival in Pulmonary Metastatic Osteosarcoma

Russ Conroy
August 30th 2025
Article

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
August 30th 2025
Podcast

Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.

3 Things You Should Know About Evolving Strategies in SCLC: Limited-Stage Advances, Frontline Innovation, and Postplatinum Progress

ONCOLOGY Staff
August 30th 2025
Article

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
August 30th 2025
Podcast

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

ONCOLOGY Staff
August 30th 2025
Article

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved a 1-year event-free survival.

OST-HER2 Shows Significant EFS Improvement in Metastatic Lung Osteosarcoma

Roman Fabbricatore
August 30th 2025
Article
Related Content

Phase 2b findings demonstrate improved 2-year survival outcomes with OST-HER2 compared with historical control data.

OST-HER2 Yields Significant Survival in Pulmonary Metastatic Osteosarcoma

Russ Conroy
August 30th 2025
Article

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
August 30th 2025
Podcast

Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.

3 Things You Should Know About Evolving Strategies in SCLC: Limited-Stage Advances, Frontline Innovation, and Postplatinum Progress

ONCOLOGY Staff
August 30th 2025
Article

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
August 30th 2025
Podcast

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

ONCOLOGY Staff
August 30th 2025
Article

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved a 1-year event-free survival.

OST-HER2 Shows Significant EFS Improvement in Metastatic Lung Osteosarcoma

Roman Fabbricatore
August 30th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.